Suraksha Diagno.

Suraksha Diagnostic Limited reported a robust 30.3% year-on-year growth in total income for Q3 FY26, reaching INR 783.09 million. This growth was primarily fueled by a combination of volume expansion from new centers and an improved product mix, particularly from the genomics vertical. The number of tests performed increased by 30.7% year-over-year to 2.06 million, and patients served grew by 23% to 0.36 million in the quarter, demonstrating strong operational momentum.

The company has made significant strides in advanced diagnostics, establishing the first complete genomic lab in Eastern India, offering cytogenetics, microarray, PCR, and next-gen sequencing. All molecular lab tests are CAP validated. Furthermore, Suraksha is building one of the first digital pathology platforms under the leadership of Dr. Geetashree and applying AI for CT and MRI reporting, aiming for quicker turnaround times and improved efficiency. These initiatives are expected to drive future growth and differentiate the company.

Suraksha's aggressive network expansion saw 12 new centers fully commissioned and operational within nine months, with an additional six facilities currently in the execution phase for Q4 FY26. This expansion, while driving topline growth, led to a temporary compression in EBITDA margins, which stood at 30.6% in Q3 FY26, down from 32.1% for the nine-month period. The management views this as a conscious investment in scale, expecting margins to improve from Q3 FY27 as the new centers mature and achieve economies of scale.

The genomics and molecular vertical, branded 'Suraksha Sutra,' has garnered significant clinical adoption, proving to be a key differentiator against price commoditization in routine testing. The current run rate for genomics is INR 2.1-2.2 million per month, with Q3 contributing INR 53 lakhs. The company projects this vertical to achieve an annual revenue run rate of INR 4+ crores for FY27, highlighting its strategic importance and growth potential.

The company maintains a very healthy financial position with negligible gross debt, reported at INR 1-1.5 crores, and a positive net cash position of approximately INR 29 crores. For FY27, Suraksha plans to add 12-15 new centers, excluding PPP projects, with an estimated capex of INR 70 crores. Management explicitly stated a preference for deploying capital in centers with better margins and manageable receivables, thus generally avoiding PPP models due to their low-margin and high-receivable nature.

Suraksha positions itself as the leading organized diagnostic player in Eastern India, emphasizing its complete genomic lab and advanced technological capabilities. While acknowledging the entry of larger players like Dr. Lal and Metropolis into genomics, Suraksha believes its regional focus, faster turnaround times for specialized tests, and strong technology team provide a distinct competitive advantage. The company aims to reach 100 centers by FY28, further solidifying its market presence.